We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
- Authors
Strumberg, Dirk; Schultheis, Beate; Scheulen, M E; Hilger, R A; Krauss, J; Marschner, N; Lordick, F; Bach, F; Reuter, D; Edler, L; Mross, K
- Abstract
Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR. Based on phase I data, the recommended dose has been established at 200 mg weekly. This study was aimed at evaluating the safety and efficacy of nimotuzumab monotherapy in patients (pts) with locally advanced or metastatic pancreatic cancer.
- Publication
Investigational new drugs, 2012, Vol 30, Issue 3, p1138
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-010-9619-8